Jun. 03 Bio-Rad Laboratories, Inc. Presents at Jefferies Global Healthcare Conference 2026, Jun-03-2026 08:45 AM
May. 19 Bio-Rad Laboratories, Inc. Presents at RBC Capital Markets Global Healthcare Conference 2026, May-19-2026 08:30 AM
May. 18 Bio-Rad Laboratories Draws Elliott Investment as Activist Investor Pushes for Turnaround MT
May. 18 Elliott Investment Management LP Urges Improvement In Share Price And Value Creation for Shareholders CI
May. 17 Elliott builds big stake in life-science tools supplier Bio-Rad Labs, WSJ reports RE
May. 17 Activist investor Elliott builds stake in life-science tools supplier Bio-Rad Laboratories, WSJ reports RE
May. 17 Activist Elliott Investment Management has built a sizable stake in Bio-Rad Laboratories - WSJ RE
May. 15 Bio-Rad Laboratories' Sales Growth Set to Recover in 2027, RBC Says MT
May. 11 Bio-Rad to Participate in Upcoming Investor Conferences AQ
May. 08 Bio-Rad to Participate in Upcoming Investor Conferences BU
May. 01 Bio-Rad Laboratories, Inc., Q1 2026 Earnings Call, Apr 30, 2026
Apr. 30 Bio Rad Laboratories : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) PU
Apr. 30 Bio-Rad Laboratories Q1 Adjusted Earnings Fall, Revenue Rises MT
Apr. 30 Bio-Rad: Q1 Earnings Snapshot AQ
Apr. 30 Earnings Flash (BIO) Bio-Rad Laboratories, Inc. Reports Q1 Revenue $592.1M, vs. FactSet Est of $589.9M MT
Apr. 30 Earnings Flash (BIO) Bio-Rad Laboratories, Inc. Posts Q1 Adjusted EPS $1.89 per Share, vs. FactSet Est of $1.97 MT
Apr. 30 Tranche Update on Bio-Rad Laboratories, Inc.'s Equity Buyback Plan announced on July 20, 2023. CI
Apr. 30 Bio-Rad Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
Apr. 30 Bio-Rad Reports First-Quarter 2026 Financial Results BU
Apr. 16 Bio-Rad to Report First-Quarter 2026 Financial Results on Thursday, April 30, 2026 BU
Apr. 07 Citigroup Downgrades Bio-Rad Laboratories to Neutral From Buy, Adjusts Price Target to $300 From $375 MT
Feb. 13 UBS Adjusts Price Target on Bio-Rad Laboratories to $335 From $350, Maintains Buy Rating MT
Feb. 12 Bio-Rad Laboratories, Inc., Q4 2025 Earnings Call, Feb 12, 2026
Feb. 12 Bio-Rad Laboratories Q4 Adjusted Earnings Fall, Revenue Rises; Shares Drop After Hours MT
Feb. 12 Earnings Flash (BIO) Bio-Rad Laboratories, Inc. Reports Q4 Revenue $693.2M, vs. FactSet Est of $688.8M MT
No results match your criteria
  1. Stock Market
  2. Stocks
  3. BIO Stock
  4. News Bio-Rad Laboratories, Inc.